메뉴 건너뛰기




Volumn 8, Issue 7, 2013, Pages 1423-1428

Discovery of a selective irreversible BMX inhibitor for prostate cancer

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; BMXIN 1; PROTEIN KINASE B INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

EID: 84880532700     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb4000629     Document Type: Article
Times cited : (42)

References (16)
  • 1
    • 0034693754 scopus 로고    scopus 로고
    • Signaling network of the Btk family kinases
    • Qiu, Y. and Kung, H. J. (2000) Signaling network of the Btk family kinases Oncogene 19, 5651-5661
    • (2000) Oncogene , vol.19 , pp. 5651-5661
    • Qiu, Y.1    Kung, H.J.2
  • 2
    • 36349003312 scopus 로고    scopus 로고
    • Activation of nonreceptor tyrosine kinase Bmx/Etk mediated by phosphoinositide 3-kinase, epidermal growth factor receptor, and ErbB3 in prostate cancer cells
    • Jiang, X., Borgesi, R. A., McKnight, N. C., Kaur, R., Carpenter, C. L., and Balk, S. P. (2007) Activation of nonreceptor tyrosine kinase Bmx/Etk mediated by phosphoinositide 3-kinase, epidermal growth factor receptor, and ErbB3 in prostate cancer cells J. Biol. Chem. 282, 32689-32698
    • (2007) J. Biol. Chem. , vol.282 , pp. 32689-32698
    • Jiang, X.1    Borgesi, R.A.2    McKnight, N.C.3    Kaur, R.4    Carpenter, C.L.5    Balk, S.P.6
  • 5
    • 77954370361 scopus 로고    scopus 로고
    • Compensatory upregulation of tyrosine kinase Etk/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells
    • Dai, B., Chen, H., Guo, S., Yang, X., Linn, D. E., Sun, F., Li, W., Guo, Z., Xu, K., Kim, O., Kong, X., Melamed, J., Qiu, S., Chen, H., and Qiu, Y. (2010) Compensatory upregulation of tyrosine kinase Etk/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells Cancer Res. 70, 5587-5596
    • (2010) Cancer Res. , vol.70 , pp. 5587-5596
    • Dai, B.1    Chen, H.2    Guo, S.3    Yang, X.4    Linn, D.E.5    Sun, F.6    Li, W.7    Guo, Z.8    Xu, K.9    Kim, O.10    Kong, X.11    Melamed, J.12    Qiu, S.13    Chen, H.14    Qiu, Y.15
  • 6
    • 53149132043 scopus 로고    scopus 로고
    • The development of HKI-272 and related compounds for the treatment of cancer
    • Wissner, A. and Mansour, T. S. (2008) The development of HKI-272 and related compounds for the treatment of cancer Arch. Pharm. 341, 465-477
    • (2008) Arch. Pharm. , vol.341 , pp. 465-477
    • Wissner, A.1    Mansour, T.S.2
  • 11
    • 77957903550 scopus 로고    scopus 로고
    • Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)- 9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1 H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer
    • Liu, Q., Chang, J. W., Wang, J., Kang, S. A., Thoreen, C. C., Markhard, A., Hur, W., Zhang, J., Sim, T., Sabatini, D. M., and Gray, N. S. (2010) Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9- (quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1 H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer J. Med. Chem. 53, 7146-7155
    • (2010) J. Med. Chem. , vol.53 , pp. 7146-7155
    • Liu, Q.1    Chang, J.W.2    Wang, J.3    Kang, S.A.4    Thoreen, C.C.5    Markhard, A.6    Hur, W.7    Zhang, J.8    Sim, T.9    Sabatini, D.M.10    Gray, N.S.11


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.